Publications by authors named "Daniel Stroyakovsky"
Eur J Cancer
December 2013
Article Synopsis
- The OCTAVIA study tested a treatment combining bevacizumab with weekly paclitaxel and carboplatin for newly diagnosed ovarian cancer patients.
- The results showed that the median progression-free survival was 23.7 months, surpassing the initial target of 18 months, with a good safety profile.
- Most patients tolerated the treatment well, with only a small percentage experiencing severe side effects, confirming the regimen's effectiveness and tolerability.
